BPI-7711

DRUG4 trials

Sponsors

Beta Pharma Shanghai, Beta Pharma, Inc.

Conditions

NSCLC

Phase 1

A Phase I Study to Determine the Effect of Food on the Pharmacokinetic Profile of BPI-7711

CompletedNCT04135820

Beta Pharma, Inc.NSCLC

Start: 2019-12-17End: 2020-03-25Updated: 2020-07-09

A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711

CompletedNCT04135833

Beta Pharma, Inc.NSCLC

Start: 2019-12-12End: 2020-07-22Updated: 2021-04-22

Phase 2

A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive

CompletedNCT03812809

Beta Pharma ShanghaiNSCLC

Start: 2019-07-05End: 2022-01-24Updated: 2022-05-19

Phase 3

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

Active, not recruitingNCT03866499

Beta Pharma ShanghaiNSCLC

Start: 2021-04-30End: 2025-12-30Updated: 2024-08-07

Related Papers

Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study.

2025-02-039 citations

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

BMC Medicine2023-01-0811 citations

Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study.

2022-08-2919 citations